Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor i receptor and vascular endothelial growth factor-A: Prognostic and predictive markers in triple-negative and non-triple-negative breast cancer

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 851-864

  Bahhnassy, Abeer ^a   Mohanad, Marwa ^b   Shaarawy, Sabry ^c   Ismail, Manal F ^d   El Bastawisy, Ahmed ^c   Ashmawy, Abeer M ^c   Zekri, Abdel Rahman ^c  

^a NATIONAL CANCER INSTITUTE   (Egypt)

^b Misr University for Science and Technology   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

Insulin growth factor insulin growth factor receptor I; Prognosis; Transforming growth factor ; Triple negative breast cancer; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; VEGFA PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NON TRIPLE NEGATIVE BREAST CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; BIOSYNTHESIS; BLOOD; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; PROGNOSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, IGF TYPE 1; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84926683609     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3560     Document Type: Article

References (59)

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. Litzenburger BC, Creighton CJ, Tsimelzon A, et al: High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res 17: 2314-2327, 2011.
3. Rakha EA, Reis-Filho JS and Ellis IO: Basal-like breast cancer: a critical review. J Clin Oncol 26: 2568-2581, 2008.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
5. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26, 1275-1281, 2008.
6. Brouckaert O, Wildiers H, Floris G and Neven P: Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 4, 511-520, 2012
7. Cao H, Yan M, Wang S, Zheng T, Xu R, Chen Y and Liu Y: Clinical characteristics and prognosis of triple-negative breast cancer. Chin-Ger J Clin Oncol 8: 471-475, 2009.
8. Oakman C, Moretti E, Galardi F, Biagioni C, Santarpia L, Biganzoli L and Di Leo A: Adjuvant systemic treatment for individual patients with triple negative breast cancer. Breast 20 (Suppl 3): S135-S141, 2011.
9. Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H, Ishikawa T, Wakasa K and Hirakawa K: Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer 103: 249-255, 2010.
10. Dumont N, Bakin AV and Arteaga CL: Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J Biol Chem 278: 3275-3285, 2003.
11. Tan AR, Alexe G and Reiss M: Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 115: 453-495, 2009.
12. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, et al: Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 60: 2898-2905, 2000.
13. George ML, Eccles SA, Tutton MG, Abulafi AM and Swift RI: Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 6: 3147-3152, 2000.
14. Pollak MN, Schernhammer ES and Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518, 2004.
15. Hankinson SE: Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer. Adv Exp Med Biol 617: 161-169, 2008.
16. Reiss K, Wang JY, Romano G, Furnari FB, Cavenee WK, Morrione A, Tu X and Baserga R: IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 19: 2687-2694, 2000.
17. Valentinis B, Navarro M, Zanocco-Marani T, Edmonds P, McCormick J, Morrione A, Sacchi A, Romano G, Reiss K and Baserga R: Insulin receptor substrate-1, p70S6K, and cell size in transformation and differentiation of hemopoietic cells. J Biol Chem 275: 25451-25459, 2000.
18. Guerra FK, Eijan AM, Puricelli L, Alonso DF, Bal de Kier Joffé E, Kornblihgtt AR, Charreau EH and Elizalde PV: Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Int J Cancer 65: 812-820, 1996.
19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5, 649-655, 1982.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
21. Ivanović V, Todorović-Raković N, Demajo M, Nesković-Konstantinović Z, Subota V, Ivanisević-Milovanović O and Nikolić-Vukosavljević D: Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 39: 454-461, 2003.
22. Jones C, Nonni AV, Fulford L, Merrett S, Chaggar R, Eusebi V and Lakhani SR: CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 85: 422-427, 2001.
23. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
24. Wang X, Chao L, Ma G, Chen L, Tian B, Zang Y and Sun J: Increased expression of osteopontin in patients with triple-negative breast cancer. Eur J Clin Invest 38: 438-446, 2008.
25. Sheen-Chen SM, Chen HS, Sheen CW, Eng HL and Chen WJ: Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg 136, 937-940, 2001.
26. Massagué J, Cheifetz S, Laiho M, Ralph DA, Weis FM and Zentella A: Transforming growth factor-beta. Cancer Surv 12: 81-103, 1992.
27. Reiss M: TGF-beta and cancer. Microbes Infect 1: 1327-1347, 1999.
28. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al: Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273, 2007.
29. Buck M, von der Fecht J and Knabbe C: Antiestrogenic regulation of transforming growth factor beta receptors I and II in human breast cancer cells. Ann NY Acad Sci 963, 140-143, 2002.
30. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL and Massagué J: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102: 13909-13914, 2005.
31. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR and Guise TA: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197-206, 1999.
32. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR and Wakefield LM: TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112: 1116-1124, 2003.
33. Kingsley LA, Fournier PG, Chirgwin JM and Guise TA: Molecular biology of bone metastasis. Mol Cancer Ther 6, 2609-2617, 2007.
34. Kareddula A, Zachariah E, Notterman D and Reiss M: Transforming growth factor-b signaling strength determines target gene expression profile in human keratinocytes. J Epithel Biol Pharmaco 1, 40-94, 2008.
35. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, Marrogi OL and Freeman SM: Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 74: 492-501, 1997.
36. Gorsch SM, Memoli VA, Stukel TA, Gold LI and Arrick BA: Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52: 6949-6952, 1992.
37. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM and Berthois Y: Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 94: 239-246, 2006.
38. Dave H, Shah M, Trivedi S and Shukla S: Prognostic utility of circulating transforming growth factor beta 1 in breast cancer patients. Int J Biol Markers 27: 53-59, 2012.
39. Taha FM, Zeeneldin AA, Helal AM, Gaber AA, Sallam YA, Ramadan H and Moneer MM: Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer. Clin Biochem 42: 1420-1426, 2009.
40. Berns EM, Klijn JG, Look MP, et al: Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res 9: 1253-1258, 2003.
41. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG and Klijn JG: High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61: 5407-5414, 2001.
42. Greenberg S and Rugo HS: Triple-negative breast cancer: role of antiangiogenic agents. Cancer J 16: 33-38, 2010.
43. Björndahl M, Cao R, Nissen LJ, et al: Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 102: 15593-15598, 2005.
44. Moschos SJ and Mantzoros CS: The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63: 317-332, 2002.
45. Rubin R and Baserga R: Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 73: 311-331, 1995.
46. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R and Barrett JC: Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 57: 4667-4672, 1997.
47. Gooch JL, Van Den Berg CL and Yee D: Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56: 1-10, 1999.
48. Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, et al: Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res 9: 4722-4729, 2003.
49. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K and Vogel V: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91: 1829-1846, 1999.
50. Yarden RI, Wilson MA and Chrysogelos SA: Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem 81 (Suppl 36): 232-246, 2001.
51. Haffner MC, Petridou B, Peyrat JP, Révillion F, Müller-Holzner E, Daxenbichler G, Marth C and Doppler W: Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer 7: 136, 2007.
52. Shin A, Ren Z, Shu XO, Cai Q, Gao YT and Zheng W: Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat 105: 55-61, 2007.
53. Minami CA, Chung DU and Chang HR: Management options in triple-negative breast cancer. Breast Cancer (Auckl) 5: 175-199, 2011.
54. Sarfstein R, Maor S, Reizner N, Abramovitch S and Werner H: Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol Cell Endocrinol 252: 241-246, 2006.
55. Valentinis B, Romano G, Peruzzi F, Morrione A, Prisco M, Soddu S, Cristofanelli B, Sacchi A and Baserga R: Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J Biol Chem 274: 12423-12430, 1999.
56. Munagala R, Aqil F and Gupta RC: Promising molecular targeted therapies in breast cancer. Indian J Pharmacol 43: 236-245, 2011.
57. Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N and Fujiwara Y: Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 35: 1537-1542, 2004.
58. Pizon M, Zimon DS, Pachmann U and Pachmann K: Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients. PLoS One 8: e56836, 2013.
59. Grau AM, Wen W, Ramroopsingh DS, Gao YT, Zi J, Cai Q, Shu XO and Zheng W: Circulating transforming growth factor-beta-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 112: 335-341, 2008.